Neuroinflammation occurs immediately following spinal cord injury (SCI) and is associated with poor neurological outcomes and contributes to secondary sequalae, including the development and maintenance of below-level neuropathic pain. Therapeutic strategies aimed at reducing neuroinflammation could, therefore, prevent tissue damage and promote neurological recovery after SCI. miRNAs are short, non-coding single-stranded RNA molecules that are found in every human tissue and biofluid and have the ability to cross the blood-brain barrier, making them excellent candidate biomarkers for neuro-trauma related conditions, neuro-recovery, and response to various neuroprotective interventions. These researchers have identified several miRNAs that are elevated in acute SCI and are associated with neuropathic pain. They propose to assess the predictive value of these biomarkers to identify individuals who experience neurological recovery or develop neuropathic pain the first year after SCI.